{"filing":{"accession_number":"0001437749-26-028109","cik":"0001091596","ticker":"AURX","company_name":"Nuo Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"aurx20260816c_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/aurx20260816c_8k.htm"},"events":[{"id":28070,"run_id":25654,"accession_number":"0001437749-26-028109","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a straightforward earnings release disclosing Q2 2026 financial results for Nuo Therapeutics. The filing explicitly states \"On August 17, 2026, Nuo Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026\" under Item 2.02. The press release includes consolidated balance sheets and statements of operations showing revenue of $1.77M (Q2) and $3.07M (H1 2026), both up over 150% year-over-year, along with operational metrics and business updates. This is material to investors assessing the company's financial performance and trajectory.","company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29869,"accession_number":"0001437749-26-028109","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing Q2 2026 financial results for Nuo Therapeutics. The filing explicitly states \"On August 17, 2026, Nuo Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026\" under Item 2.02. The press release includes consolidated balance sheets and statements of operations showing revenue of $1.77M (Q2) and $3.07M (H1 2026), both up over 150% year-over-year, along with operational metrics and business updates. This is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:56.644453+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29869,"accession_number":"0001437749-26-028109","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing Q2 2026 financial results for Nuo Therapeutics. The filing explicitly states \"On August 17, 2026, Nuo Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026\" under Item 2.02. The press release includes consolidated balance sheets and statements of operations showing revenue of $1.77M (Q2) and $3.07M (H1 2026), both up over 150% year-over-year, along with operational metrics and business updates. This is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:56.644453+00:00","company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","filing_date":"2026-08-17"}]}